E-mail: escudie@igr.fr
Odborné práce publikované na Linkos.cz
Přehled odborných textů publikovaných autorem na portálu Linkos.cz. Jsou zde uvedeny knihy a brožury, články v Klinické onkologii, tuzemská abstrakta z databáze abstrakt a další texty. Rejstřík není v žádném případě úplným autorským rejstříkem, protože jsou zde uvedeny pouze texty zveřejněné na portálu Linkos.cz.
Publikovaná abstrakta
- Bevacizumab (BEV) and interferon (IFN) therapy does not increase risk of cardiac events in metastatic renal cell carcinoma (mRCC)
- Bevacizumab/interferon-alpha2a provides a progression-free survival benefit in all prespecified patient subgroups as first-line treatment of metastatic renal cell carcinoma (AVOREN)
- Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-á2a (IFN) in metastatic renal cell carcinoma (mRCC)
- First-line bevacizumab + reduced-dose interferon-alpha2a in patients (pts) with metastatic renal cell carcinoma (mRCC): an update on overall survival
- First-line bevacizumab improves progression-free survival with lower doses of interferon[alpha]2a in the treatment of patients with metastatic renal cell carcinoma (AVOREN)
- Pancreatic metastases from renal cell carcinoma: Prognostic relevance and outcome in patients treated with targeted agents.
- PREDICT (Patient characteristics in Renal cell carcinoma and Daily practice Treatment with Nexavar) global non-interventional study: first interim results
- PREDICT (Patient Characteristics in REnal Cell Carcinoma and Daily PractICe Treatment With Sorafenib) Non-interventional Study − Final Report
- SORAFENIB IN PATIENTS WITH RENAL CELL CARCINOMA (RCC) AND BASELINE HYPERTENSION OR DIABETES: SUBANALYSIS OF THE NON-INTERVENTIONAL PREDICT STUDY
- SORAFENIB IN PATIENTS WITH RENAL CELL CARCINOMA AND BRAIN, BONE OR LUNG METASTASES: SUBANALYSIS OF THE NON-INTERVENTIONAL PREDICT STUDY
- What is the impact of subsequent antineoplastic therapy on overall survival (OS) following first-line bevacizumab (BEV)/interferon-alpha2a (IFN) in metastatic renal cell carcinoma (mRCC)? - Experience from AVOREN
